Institution
Second Affiliated Hospital of Fujian Medical University
Also known as: 福建医科大学附属第二医院
- 15running trials
- 1closed trial
- 5,301publications (OpenAlex)
Running trials
Not yet recruiting
Not yet recruiting
Recruiting
Recruiting
Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis
Active, not recruiting
A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE
Recruiting
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Not yet recruiting
Recruiting
Recruiting
Active, not recruiting
Methylprednisolone Adjunctive to Endovascular Thrombectomy for Stroke
Active, not recruiting
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Active, not recruiting
Recruiting
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Bronchiectasis2 recruiting
- Liver and biliary tract cancer2 recruiting
- Metastatic breast cancer2 recruiting
- Diffuse large B-cell lymphoma1 recruiting
- Hepatitis B1 recruiting
- High blood pressure1 recruiting
- Rheumatoid arthritis1 recruiting
- Triple-negative breast cancer1 recruiting
Closed trials
Registry name variants (5)
Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.
The Second Affiliated Hospital of Fujian Medical University
Quanzhou, Fujian 362000
11 trials
Second Affiliated Hospital of Fujian Medical University
Quanzhou, Fujian
2 trials
Fujian Medical University Affiliated Second Hospital
Quanzhou, Fujian 362002
1 trial
Contact: Nadene Zack, MS
The Second Affiliated Hospital of Fujian Medical University (Site 0671)
Quanzhou, Fujian 362000
1 trial
The Second Affiliated Hospital Of Fujian Medical University (Site 3525)
Quanzhou, Fujian 362000
1 trial
Conditions
Diseases this institution publishes on or runs trials for.
- Optic neuritis3 works · 0 trials
Institution data: ROR 03wnxd135 (CC0-1.0)Updated 15 Nov 2026